Literature DB >> 24006273

Managing localized prostate cancer in the era of prostate-specific antigen screening.

James D Brooks1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24006273      PMCID： PMC3875624          DOI： 10.1002/cncr.28301

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  23 in total

Review 1.  The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma.

Authors:  Jonathan I Epstein; William C Allsbrook; Mahul B Amin; Lars L Egevad
Journal:  Am J Surg Pathol       Date:  2005-09       Impact factor: 6.394

2.  Use of advanced treatment technologies among men at low risk of dying from prostate cancer.

Authors:  Bruce L Jacobs; Yun Zhang; Florian R Schroeck; Ted A Skolarus; John T Wei; James E Montie; Scott M Gilbert; Seth A Strope; Rodney L Dunn; David C Miller; Brent K Hollenbeck
Journal:  JAMA       Date:  2013-06-26       Impact factor: 56.272

3.  High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases.

Authors:  W A Sakr; D J Grignon; J D Crissman; L K Heilbrun; B J Cassin; J J Pontes; G P Haas
Journal:  In Vivo       Date:  1994 May-Jun       Impact factor: 2.155

4.  Time trends and local variation in primary treatment of localized prostate cancer.

Authors:  Matthew R Cooperberg; Jeanette M Broering; Peter R Carroll
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

5.  Mortality results from a randomized prostate-cancer screening trial.

Authors:  Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Edward P Gelmann; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Richard B Hayes; Barnett S Kramer; Grant Izmirlian; Anthony B Miller; Paul F Pinsky; Philip C Prorok; John K Gohagan; Christine D Berg
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

6.  The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?

Authors:  Thomas A Stamey; Mitchell Caldwell; John E McNeal; Rosalie Nolley; Marci Hemenez; Joshua Downs
Journal:  J Urol       Date:  2004-10       Impact factor: 7.450

7.  Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository.

Authors:  Lisa F Newcomb; James D Brooks; Peter R Carroll; Ziding Feng; Martin E Gleave; Peter S Nelson; Ian M Thompson; Daniel W Lin
Journal:  Urology       Date:  2009-09-16       Impact factor: 2.649

8.  Lower body mass index is associated with a higher prostate cancer detection rate and less favorable pathological features in a biopsy population.

Authors:  Joseph C Presti; Una Lee; James D Brooks; Martha K Terris
Journal:  J Urol       Date:  2004-06       Impact factor: 7.450

Review 9.  Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings.

Authors:  J I Epstein; D W Chan; L J Sokoll; P C Walsh; J L Cox; H Rittenhouse; R Wolfert; H B Carter
Journal:  J Urol       Date:  1998-12       Impact factor: 7.450

10.  Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer.

Authors:  Laurence Klotz; Liying Zhang; Adam Lam; Robert Nam; Alexandre Mamedov; Andrew Loblaw
Journal:  J Clin Oncol       Date:  2009-11-16       Impact factor: 44.544
View more
  11 in total

1.  Loss of Expression of AZGP1 Is Associated With Worse Clinical Outcomes in a Multi-Institutional Radical Prostatectomy Cohort.

Authors:  James D Brooks; Wei Wei; Jonathan R Pollack; Robert B West; Jun Ho Shin; John B Sunwoo; Sarah J Hawley; Heidi Auman; Lisa F Newcomb; Jeff Simko; Antonio Hurtado-Coll; Dean A Troyer; Peter R Carroll; Martin E Gleave; Daniel W Lin; Peter S Nelson; Ian M Thompson; Lawrence D True; Jesse K McKenney; Ziding Feng; Ladan Fazli
Journal:  Prostate       Date:  2016-06-21       Impact factor: 4.104

2.  Optimizing Time to Treatment to Achieve Durable Biochemical Disease Control after Surgery in Prostate Cancer: A Multi-Institutional Cohort Study.

Authors:  Shivanshu Awasthi; Travis Gerke; Jong Y Park; Francis A Asamoah; Vonetta L Williams; Angelina K Fink; Rajesh Balkrishnan; David I Lee; S Bruce Malkowicz; Priti Lal; Jasreman Dhillon; Julio M Pow-Sang; Timothy R Rebbeck; Kosj Yamoah
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-11-09       Impact factor: 4.254

3.  Diagnosis of prostate cancer by desorption electrospray ionization mass spectrometric imaging of small metabolites and lipids.

Authors:  Shibdas Banerjee; Richard N Zare; Robert J Tibshirani; Christian A Kunder; Rosalie Nolley; Richard Fan; James D Brooks; Geoffrey A Sonn
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-14       Impact factor: 11.205

4.  PSA Testing Use and Prostate Cancer Diagnostic Stage After the 2012 U.S. Preventive Services Task Force Guideline Changes.

Authors:  Christopher J Magnani; Kevin Li; Tina Seto; Kathryn M McDonald; Douglas W Blayney; James D Brooks; Tina Hernandez-Boussard
Journal:  J Natl Compr Canc Netw       Date:  2019-07-01       Impact factor: 11.908

5.  Protein signatures to distinguish aggressive from indolent prostate cancer.

Authors:  Fernando Garcia-Marques; Shiqin Liu; Sarah M Totten; Abel Bermudez; Cheylene Tanimoto; En-Chi Hsu; Rosalie Nolley; Amy Hembree; Tanya Stoyanova; James D Brooks; Sharon J Pitteri
Journal:  Prostate       Date:  2022-01-31       Impact factor: 4.104

6.  Overall Survival in Patients with Localized Prostate Cancer in the US Veterans Health Administration: Is PIVOT Generalizable?

Authors:  Philip V Barbosa; I-Chun Thomas; Sandy Srinivas; Mark K Buyyounouski; Benjamin I Chung; Glenn M Chertow; Steven M Asch; Todd H Wagner; James D Brooks; John T Leppert
Journal:  Eur Urol       Date:  2016-03-02       Impact factor: 20.096

7.  In Vivo Imaging of Methionine Aminopeptidase II for Prostate Cancer Risk Stratification.

Authors:  Jinghang Xie; Meghan A Rice; Zixin Chen; Yunfeng Cheng; En-Chi Hsu; Min Chen; Guosheng Song; Liyang Cui; Kaixiang Zhou; Jessa B Castillo; Chiyuan A Zhang; Bin Shen; Frederick T Chin; Christian A Kunder; James D Brooks; Tanya Stoyanova; Jianghong Rao
Journal:  Cancer Res       Date:  2021-02-26       Impact factor: 13.312

8.  Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients.

Authors:  James D Brooks; Wei Wei; Sarah Hawley; Heidi Auman; Lisa Newcomb; Hilary Boyer; Ladan Fazli; Jeff Simko; Antonio Hurtado-Coll; Dean A Troyer; Peter R Carroll; Martin Gleave; Raymond Lance; Daniel W Lin; Peter S Nelson; Ian M Thompson; Lawrence D True; Ziding Feng; Jesse K McKenney
Journal:  PLoS One       Date:  2015-07-14       Impact factor: 3.240

Review 9.  Comparative effectiveness of prostate cancer treatments for patient-centered outcomes: A systematic review and meta-analysis (PRISMA Compliant).

Authors:  Ravishankar Jayadevappa; Sumedha Chhatre; Yu-Ning Wong; Marsha N Wittink; Ratna Cook; Knashawn H Morales; Neha Vapiwala; Diane K Newman; Thomas Guzzo; Alan J Wein; Stanley B Malkowicz; David I Lee; Jerome S Schwartz; Joseph J Gallo
Journal:  Medicine (Baltimore)       Date:  2017-05       Impact factor: 1.889

10.  Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancer.

Authors:  Debashis Sahoo; Wei Wei; Heidi Auman; Antonio Hurtado-Coll; Peter R Carroll; Ladan Fazli; Martin E Gleave; Daniel W Lin; Peter S Nelson; Jeff Simko; Ian M Thompson; Robin J Leach; Dean A Troyer; Lawrence D True; Jesse K McKenney; Ziding Feng; James D Brooks
Journal:  Oncotarget       Date:  2018-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.